Trial Profile
A phase II multicenter study of erbitux (cetuximab) in patients with metastatic colorectal carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Dec 2008 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 05 Sep 2007 Status change from in progress to completed
- 25 Sep 2005 New trial record.